Dare Bioscience (DARE) FCF Margin (2014 - 2025)
Dare Bioscience's (DARE) quarterly FCF Margin came in at 119.52% in Q4 2025, up 861782.0% on a YoY basis from N/an in Q4 2024, and up 100.42% quarter-over-quarter from 28728.65% in Q3 2025.
Powered by 
Analysis
Dare Bioscience (DARE) FCF Margin (2014 - 2025) Analysis & Trends
Dare Bioscience (DARE) has reported FCF Margin for 7 consecutive years, with 119.52% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 861782.0% year-over-year to 119.52%; the trailing twelve-month figure through Dec 2025 stood at 998.38% (down 5108535.0% YoY), and the FY2025 full-year result was 998.38%, down 5108535.0% from the prior year.
- FCF Margin rose to 119.52% in Q4 2025 per DARE's latest filing, from 28728.65% in the prior quarter.
- Across five years, FCF Margin topped out at 54669.37% in Q2 2024 and bottomed at 69528.19% in Q1 2024.
- Historically, FCF Margin has averaged 6012.98% across 4 years, with a median of 795.76% in 2023.
- The widest YoY moves for FCF Margin: up 4727888 bps in 2025, down 3010108 bps in 2025.
- Over 4 years, FCF Margin stood at 84.45% in 2022, then sank by 475 bps to 485.85% in 2023, then sank by 1649 bps to 8498.3% in 2024, then surged by 101 bps to 119.52% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 119.52%, 28728.65%, and 24568.29% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.64 Bn | 192.65 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.82 Bn | 176.65 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 131.16 Bn | 123.31 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.67 Bn | 73.67 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.91 Bn | 48.77 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.05 Bn | 29.05 Bn | 1.16 Mn | -18,629.40% |
| 10 | Dare Bioscience | 10.65 Mn | -1.96 Mn | -132,343.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 119.52% |
| Sep 30, 2025 | -28,728.65% |
| Jun 30, 2025 | 24,568.29% |
| Mar 31, 2025 | -22,249.31% |
| Dec 31, 2024 | -8,498.30% |
| Sep 30, 2024 | -15,129.42% |
| Jun 30, 2024 | 54,669.37% |
| Mar 31, 2024 | -69,528.19% |
| Dec 31, 2023 | -485.85% |
| Sep 30, 2023 | -795.76% |
| Jun 30, 2022 | -84.45% |
| Jun 30, 2017 | -17.07% |
| Mar 31, 2017 | -4.24% |
| Dec 31, 2016 | -26.50% |
| Jun 30, 2014 | -9,842.42% |
| Mar 31, 2014 | -9,968.09% |